Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Activin A

Activin A

Brief Information

Name:Activin receptor type-1
Target Synonym:ACTR-I,ACVR1,Activin A Receptor Type 1,Serine/Threonine-Protein Kinase Receptor R1,Activin A Receptor, Type I,ACVRLK2,SKR1,Activin A Receptor, Type II-Like Kinase 2,Hydroxyalkyl-Protein Kinase,Activin Receptor Type-1,EC 2.7.11.30,ACVR1A,ACTRI,EC:2.7.11.30,TSR-I,ALK2,TSRI,FOP,Activin Receptors, Type I,ALK-2,Activin receptor type I,TGF-B superfamily receptor type I,EC 2.7.11,Activin receptor-like kinase 2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ACA-H421b Human Human Activin A / INHBA Protein, premium grade
ACA-H421b-structure
ACA-H421b-sds
ACA-H424x Human Human Latent Activin A / INHBA Protein, His Tag
ACA-H424x-structure
ACA-H424x-sds
ACRO Quality

Part of Bioactivity data

ACA-H421b-Cell-based assay
 Activin A CELL

Human Activin A, premium grade (Cat. No. ACA-H421b) inhibits the proliferation of MPC-11 cells. The specific activity of Human Activin A, premium grade is>5.00*10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (QC tested).

ACA-H424x-Cell-based assay
 Activin A CELL

The bio-activity of Human Latent Activin A, His Tag (Cat. No. ACA-H424x) was determined by dose-dependent inhibition of the proliferation of MPC-11 cells. The EC50 for this effect is typically 47-66 ng/mL (Routinely tested).

ACA-H421b-SPR
 Activin A SPR

Human Activin RIIB, His Tag (Cat. No. ACB-H5226) immobilized on CM5 Chip can bind Human Activin A, premium grade (Cat. No. ACA-H421b) with an affinity constant of 0.216 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

ACA-H424x-SPR
 Activin A SPR

Biotinylated Human Activin RIIB Protein, His,Avitag (Cat. No. ACB-H82E3) immobilized on CM5 Chip can bind Human Latent Activin A, His Tag (Cat. No. ACA-H424x) with an affinity constant of 0.147 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

Activin A,INHBA

Background

Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Conversely inhibin down regulates FSH synthesis and inhibits FSH secretion.Activins are nonglycosylated homodimers or heterodimers of various ¦Â subunits (¦ÂA, ¦ÂB, ¦ÂC, and ¦ÂE in mammals), while Inhibins are heterodimers of a unique ¦Á subunit and one of the ¦Â subunits. Activin A is a widely expressed homodimer of two ¦ÂA chains. The ¦ÂA subunit can also heterodimerize with a ¦ÂB or ¦ÂC subunit to form Activin AB and Activin AC, respectively. The 14 kDa mature human ¦ÂA chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat ¦ÂA.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Momelotinib Dihydrochloride CYT-387; GS-0387; GSK-3070785 Approved Gilead Sciences Inc, Cytopia Pty Ltd Ojjaara United States Primary Myelofibrosis; Anemia Glaxosmithkline Llc, Glaxosmithkline Plc 2023-09-15 Polycythemia; Polycythemia Vera; Anemia; Neoplasms; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BCX-9250 BCX-9250 Phase 1 Clinical Biocryst Pharmaceuticals Inc Myositis Ossificans Details
KER-047 KER-047 Phase 1 Clinical National Center For Advancing Translational Sciences Anemia, Iron-Deficiency; Myositis Ossificans Details
Itacnosertib TP-0184 Phase 1 Clinical Tolero Pharmaceuticals Inc, Sumitomo Dainippon Solid tumours; Anemia Details
BLU-782 BLU-782; IPN-60130 Phase 2 Clinical Blueprint Medicines Corp, Ipsen SA Myositis Ossificans Details
Zilurgisertib INCB-000928; INCB-00928 Phase 2 Clinical Incyte Corp Anemia; Polycythemia Vera; Kidney Diseases; Myelodysplastic Syndromes; Ossification, Heterotopic; Multiple Myeloma; Myositis Ossificans; Primary Myelofibrosis; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message